Synergy CHC Corp (NASDAQ:SNYR) Reports Q2 2025 Earnings: EPS Beat Overshadowed by Revenue Miss

SYNERGY CHC CORP (NASDAQ:SNYR) reported its second-quarter 2025 financial results, marking its tenth consecutive quarter of profitability. The company, which specializes in consumer health and wellness products, posted mixed results compared to analyst expectations, leading to a muted market reaction.

Key Financial Highlights

• Revenue Miss: The company reported revenue of $6.74 million for Q2 2025, falling short of the consensus estimate of $11.02 million. This represents a significant deviation from expectations.
• EPS Beat: Despite the revenue shortfall, Synergy CHC delivered earnings per share (EPS) of $0.17, surpassing analyst estimates of $0.0816 by 86%. This sharp increase in profitability suggests improved margins or cost efficiencies.

Market Reaction

The stock saw a slight pre-market decline of -2.07%, indicating investor caution following the earnings release. Over the past month, shares have risen 12.5%, reflecting broader optimism ahead of the report. However, the revenue miss appears to be weighing on sentiment, overshadowing the strong EPS performance.

Analyst Estimates for Future Quarters

Looking ahead, analysts expect:

• Q3 2025 Revenue: $12.34 million
• Q3 2025 EPS: $0.112
• Full-Year 2025 Revenue: $48.01 million
• Full-Year 2025 EPS: $0.4896

The company did not provide an explicit outlook in its press release, leaving investors to rely on analyst projections. The lack of forward guidance may contribute to the subdued market reaction.

Press Release Summary

Synergy CHC emphasized its tenth straight profitable quarter, reinforcing its stability in the consumer health sector. The company’s brand portfolio, including FOCUSfactor and Flat Tummy, continues to drive its business, though the revenue miss raises questions about demand or execution challenges.

For a deeper dive into Synergy CHC’s earnings and future estimates, visit the earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.